Treprostinil Dependence And Litigation Risks Will Undermine Long Term Pulmonary Hypertension Prospects

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

22 Dec 25

Updated

21 Aug 26

Views

Not Invested

Shared on 21 Aug 26

Fair value Increased 50%

LQDA: Patent Rulings Will Shape Future Pulmonary Hypertension Earnings Power

Liquidia’s fast uptake of Yutrepia is pushing expectations higher, but the next big swing factor is how patent court decisions play out and what that means for long-term access and profits. With another product in development also in the mix, the outlook now hinges on whether market share momentum continues or legal uncertainty forces a reset.

2 views

Shared on 24 Jul 26

Fair value Increased 253%

LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside

Liquidia’s outlook now hinges on two things: how fast YUTREPIA keeps winning new patients, and whether upcoming patent decisions let it stay on the market in its biggest uses. With analysts turning more confident but still split, the next legal rulings could quickly reshape the company’s long-term earnings story in either direction.

11 views

Treprostinil Dependence And Litigation Risks Will Undermine Long Term Pulmonary Hypertension Prospects

LQDA: Patent Rulings Will Shape Future Pulmonary Hypertension Earnings Power

LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Liquidia

Company analysis

CEO & management